AI in Drug Discovery Quadrant Report
The Artificial Intelligence (AI) in drug discovery Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Artificial Intelligence (AI) in drug discovery. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. MarketsandMarkets 360 Quadrants evaluated over 40 companies of which the Top 24 Hydrogen Fueling Station Companies were categorized and recognized as the quadrant leaders.
The integration of Artificial Intelligence (AI) in drug discovery has the potential to significantly strengthen the market landscape. By optimizing experiments, prioritizing critical targets, and enabling virtual screening, AI accelerates research, facilitates faster identification of failures, and broadens testing diversity. It also revolutionizes drug discovery workflows by streamlining processes, automating tasks, minimizing in-process decision-making, and advancing parallel property optimization. Additionally, AI-driven tools for epitope selection, prediction, and binding analysis are expediting the development of new vaccines and therapeutics.
However, AI faces limitations, such as a lack of the nuanced understanding and creative insights that experienced researchers bring. Its application can be constrained by insufficient depth, dimensionality, and scale in data, as well as missing metadata on experimental conditions like cell culture or assay parameters. Furthermore, ethical concerns, including data privacy, algorithmic bias, and transparency in decision-making, pose challenges that may hinder market growth in the years ahead.
Attractive Opportunities in AI in Drug Discovery Market
The 360 Quadrant maps the AI in drug discovery companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the AI in drug discovery quadrant. The top criteria for product footprint evaluation included Process (Target and Lead), Use Case (Understanding Disease, Small Molecule Design and Optimization, Vaccine Design and Optimization, Antibody & Other Biologics Design and Optimization and Safety and Toxicity), Technology (Machine Learning, Natural Language Processing, Context-aware Processing and other technologies), Therapeutic Area(Oncology, Infectious Diseases, Neurology, Metabolic Diseases, Cardiovascular Diseases, Immunology and Other Therapeutic Areas), Offering and End-User.
Key Players:
Some of the prominent players are NVIDIA Corporation (US), Exscientia (UK), BenevolentAI (UK), Recursion (US), Insilico Medicine (US), Schrödinger, Inc. (US), Microsoft Corporation (US), Google (US), Atomwise Inc. (US), Illumina, Inc. (US), NuMedii, Inc. (US), XtalPi Inc. (US), Iktos (France), Tempus Labs (US), Deep Genomics, Inc. (Canada), Verge Genomics (US), BenchSci (Canada), Insitro (US), Valo Health (US), BPGbio, Inc. (US), IQVIA Inc (US), Labcorp (US), Tencent Holdings Limited (China), Predictive Oncology, Inc. (US), Celsius Therapeutics (US), CytoReason (Israel), Owkin, Inc. (US), Cloud Pharmaceuticals (US), Evaxion Biotech (Denmark), Standigm (South Korea), BIOAGE (US), Envisagenics (US), and Aria Pharmaceuticals, Inc. (US). These players are increasingly focusing on product launches and enhancements, investments, partnerships, collaborations, joint ventures, funding, acquisition, expansions, agreements, sales contracts, and alliances to strengthen their presence in the global market.
AI IN DRUG DISCOVERY MARKET ECOSYSTEM
The aspects present in this market are included in the ecosystem market map of the overall Artificial intelligence (AI) in drug discovery, and each element is defined with a list of the organizations involved. Products and services are included. The manufacturers of various products include the organizations involved in the entire process of research, product development, optimization, and launch. Vendors provide the services to end users either directly or through a collaboration with a third party.
Source: Secondary Literature, Interviews with Experts, and MarketsandMarkets Analysis
Recent Developments:
- October 2023: Recursion, in partnership with Roche and Genentech, achieved a major milestone by identifying and validating a hit series for a specific disease, activating Roche's Small Molecule Validation Program Option. Recursion will spearhead the program using its proprietary Recursion OS and digital chemistry tools. This advancement highlights their collaborative efforts to develop therapeutic programs based on Maps of Biology and Chemistry, with plans to explore novel target hypotheses across multiple CNS cell types and foster future partnerships.
- September 2023: Exscientia announced a collaboration with Merck KGaA to discover novel small-molecule drug candidates in oncology, neuroinflammation, and immunology. This multi-year partnership will combine Exscientia’s AI-driven precision drug discovery capabilities with Merck KGaA’s expertise in disease biology, clinical development, and global reach, aiming to deliver breakthrough therapeutic solutions.
- May 2023: Google Cloud introduced two AI-powered platforms—the Target and Lead Identification Suite and the Multiomics Suite—to revolutionize drug discovery and precision medicine. The Target and Lead Identification Suite facilitates efficient in silico drug design, predicts protein structures, and accelerates lead optimization, catering to biotech companies, pharmaceutical firms, and public sector organizations.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 REGIONAL SCOPE
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
2 MARKET OVERVIEW
2.1 INTRODUCTION
2.2 MARKET DYNAMICS
2.2.1 DRIVERS
2.2.1.1 Growing cross-industry collaborations and partnerships
2.2.1.2 Growing need to reduce time and cost of drug discovery and development
2.2.1.3 Patent expiry of several drugs
2.2.2 RESTRAINTS
2.2.2.1 Shortage of AI workforce and ambiguous regulatory guidelines for medical software
2.2.3 OPPORTUNITIES
2.2.3.1 Growing biotechnology industry
2.2.3.2 Emerging markets
2.2.3.3 Focus on developing human-aware AI systems
2.2.4 CHALLENGES
2.2.4.1 Limited availability of data sets
2.3 PORTER’S FIVE FORCES ANALYSIS
2.3.1 INTENSITY OF COMPETITIVE RIVALRY
2.3.2 BARGAINING POWER OF BUYERS
2.3.3 BARGAINING POWER OF SUPPLIERS
2.3.4 THREAT OF SUBSTITUTES
2.3.2 THREAT OF NEW ENTRANTS
2.4 ECOSYSTEM/MARKET MAP
2.5 CASE STUDY ANALYSIS
2.5.1 CASE STUDY 1: BRISTOL MYERS SQUIBB AND EXSCIENTIA
2.5.2 CASE STUDY 2: APEIRON LLC AND EXSCIENTIA
3 COMPETITIVE LANDSCAPE
3.1 KEY PLAYER STRATEGIES/RIGHT TO WIN
3.2 REVENUE ANALYSIS
3.3 MARKET SHARE ANALYSIS
3.4 COMPANY EVALUATION MATRIX
3.4.1 STARS
3.4.2 EMERGING LEADERS
3.4.3 PERVASIVE PLAYERS
3.4.4 PARTICIPANTS
3.4.5 COMPANY FOOTPRINT
3.5 START-UP/SME EVALUATION MATRIX
3.5.1 PROGRESSIVE COMPANIES
3.5.2 RESPONSIVE COMPANIES
3.5.3 DYNAMIC COMPANIES
3.5.4 STARTING BLOCKS
3.5.5 AI IN DRUG DISCOVERY MARKET: COMPETITIVE BENCHMARKING
3.6 COMPETITIVE SCENARIOS AND TRENDS
3.6.1 PRODUCT LAUNCHES & ENHANCEMENTS
3.6.2 DEALS
3.6.3 OTHER DEVELOPMENTS
4 COMPANY PROFILES
4.1 KEY PLAYERS
4.1.1 NVIDIA CORPORATION
4.1.1.1 Business overview
4.1.1.2 Products/Solutions/Services offered
4.1.1.3 Recent developments
4.1.1.4 MnM view
4.1.1.4.1 Key Strengths/Right to win
4.1.1.4.2 Strategic choices made
4.1.1.4.3 Weaknesses & competitive threats
4.1.2 EXSCIENTIA
4.1.2.1 Business overview
4.1.2.2 Products/Solutions/Services offered
4.1.2.3 Recent developments
4.1.2.4 MnM view
4.1.2.4.1 Key Strengths/Right to win
4.1.2.4.2 Strategic choices made
4.1.2.4.3 Weaknesses & competitive threats
4.1.3 GOOGLE
4.1.3.1 Business overview
4.1.3.2 Products/Solutions/Services offered
4.1.3.3 Recent developments
4.1.3.4 MnM view
4.1.3.4.1 Key Strengths/Right to win
4.1.3.4.2 Strategic choices made
4.1.3.4.3 Weaknesses & competitive threats
4.1.4 BENEVOLENTAI
4.1.4.1 Business overview
4.1.4.2 Products/Solutions/Services offered
4.1.4.3 Recent developments
4.1.4.4 MnM view
4.1.4.4.1 Key Strengths/Right to win
4.1.4.4.2 Strategic choices made
4.1.4.4.3 Weaknesses & competitive threats
4.1.5 RECURSION
4.1.5.1 Business overview
4.1.5.2 Products/Solutions/Services offered
4.1.5.3 Recent developments
4.1.5.4 MnM view
4.1.5.4.1 Key Strengths/Right to win
4.1.5.4.2 Strategic choices made
4.1.5.4.3 Weaknesses & competitive threats
4.1.6 INSILICO MEDICINE
4.1.6.1 Business overview
4.1.6.2 Products/Solutions/Services offered
4.1.6.3 Recent developments
4.1.7 SCHRÖDINGER, INC.
4.1.7.1 Business overview
4.1.7.2 Products/Solutions/Services offered
4.1.7.3 Recent developments
4.1.8 MICROSOFT CORPORATION
4.1.8.1 Business overview
4.1.8.2 Products/Solutions/Services offered
4.1.8.3 Recent developments
4.1.9 ATOMWISE INC.
4.1.9.1 Business overview
4.1.9.2 Products/Solutions/Services offered
4.1.9.3 Recent developments
4.1.10 ILLUMINA, INC.
4.1.10.1 Business overview
4.1.10.2 Products/Solutions/Services offered
4.1.10.3 Recent developments
4.1.11 NUMEDII, INC.
4.1.11.1 Business overview
4.1.11.2 Products/Solutions/Services offered
4.1.12 XTALPI INC.
4.1.12.1 Business overview
4.1.12.2 Products/Solutions/Services offered
4.1.12.3 Recent developments
4.1.13 IKTOS
4.1.13.1 Business overview
4.1.13.2 Products/Solutions/Services offered
4.1.13.3 Recent developments
4.1.14 TEMPUS LABS
4.1.14.1 Business overview
4.1.14.2 Products/Solutions/Services offered
4.1.14.3 Recent developments
4.1.15 DEEP GENOMICS, INC.
4.1.15.1 Business overview
4.1.15.2 Products/Solutions/Services offered
4.1.15.3 Recent developments
4.1.16 VERGE GENOMICS
4.1.16.1 Business overview
4.1.16.2 Products/Solutions/Services offered
4.1.16.3 Recent developments
4.1.17 BENCHSCI
4.1.17.1 Business overview
4.1.17.2 Products/Solutions/Services offered
4.1.17.3 Recent developments
4.1.18 INSITRO
4.1.18.1 Business overview
4.1.18.2 Products/Solutions/Services offered
4.1.18.3 Recent developments
4.1.19 VALO HEALTH
4.1.19.1 Business overview
4.1.19.2 Products/Solutions/Services offered
4.1.19.3 Recent developments
4.1.20 BPGBIO, INC.
4.1.20.1 Business overview
4.1.20.2 Products/Solutions/Services offered
4.1.20.3 Recent development
4.2 OTHER EMERGING PLAYERS
4.2.1 PREDICTIVE ONCOLOGY, INC.
4.2.2 LABCORP
4.2.3 IQVIA INC.
4.2.4 TENCENT HOLDINGS LIMITED
4.2.5 CELSIUS THERAPEUTICS
4.2.6 CYTOREASON
4.2.7 OWKIN, INC.
4.2.8 CLOUD PHARMACEUTICALS
4.2.9 EVAXION BIOTECH
4.2.10 STANDIGM
4.2.11 BIOAGE LABS
4.2.12 ENVISAGENICS
4.2.13 ARIA PHARMACEUTICALS, INC.
COMPANY PROFILES
KEY PLAYERS
NVIDIA CORPORATION
EXSCIENTIA
GOOGLE
BENEVOLENTAI
RECURSION
INSILICO MEDICINE
SCHRÖDINGER, INC.
MICROSOFT CORPORATION
ATOMWISE INC.
ILLUMINA, INC.
NUMEDII, INC.
XTALPI INC.
IKTOS
TEMPUS LABS
DEEP GENOMICS, INC.
VERGE GENOMICS
BENCHSCI
INSITRO
VALO HEALTH
BPGBIO, INC.
OTHER EMERGING PLAYERS
PREDICTIVE ONCOLOGY, INC.
LABCORP
IQVIA INC.
TENCENT HOLDINGS LIMITED
CELSIUS THERAPEUTICS
CYTOREASON
OWKIN, INC.
CLOUD PHARMACEUTICALS
EVAXION BIOTECH
STANDIGM
BIOAGE LABS
ENVISAGENICS
ARIA PHARMACEUTICALS, INC.
- Updated version of this Quadrant
- Different Company Evaluation Quadrant
- 'Startup Only' Company Evaluation Quadrant
- Region or Country specific evaluation
- Application or Industry specific evaluation ..Read More
- Submit a Briefing Request
- Question about our published research
- Request for evaluation of your organization for specific market
- Request for re-evaluation of Company Evaluation Quadrant ..Read More
